Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 205

1.

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.

Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D.

Nat Med. 2019 Dec;25(12):1938-1947. doi: 10.1038/s41591-019-0668-z. Epub 2019 Dec 2.

PMID:
31792461
2.

Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).

Wiegand J, Buggisch P, Mauss S, Boeker KHW, Klinker H, Müller T, Günther R, Serfert Y, Manns MP, Zeuzem S, Berg T, Hinrichsen H, C-Registry GH.

Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1424-1431. doi: 10.1097/MEG.0000000000001426.

PMID:
31589184
3.

Hepatitis B Vaccination in Patients with Liver Cirrhosis Evaluated for Liver Transplantation - A Simple Intervention Ensures High Adherence.

Herta T, Petroff D, Engelmann C, Herber A, Aehling N, Scheuermann U, Bartels M, Seehofer D, Berg T, Wiegand J.

Ann Transplant. 2019 Sep 13;24:527-531. doi: 10.12659/AOT.917198.

4.

Laboratory reform counteracts the WHO hepatitis C elimination strategy in Germany.

Kramer J, Wolffram I, Früh U, Bätz O, Berg T, Wiegand J.

J Viral Hepat. 2019 Dec;26(12):1493-1495. doi: 10.1111/jvh.13188. Epub 2019 Aug 22.

PMID:
31386783
5.

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.

Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M; Austrian/German NAFLD-norUDCA study group.

Lancet Gastroenterol Hepatol. 2019 Oct;4(10):781-793. doi: 10.1016/S2468-1253(19)30184-0. Epub 2019 Jul 22.

PMID:
31345778
6.

Iberogast-Induced Acute Liver Failure-Reexposure and In Vitro Assay Support Causality.

Gerhardt F, Benesic A, Tillmann HL, Rademacher S, Wittekind C, Gerbes AL, Henker R, Berg T, Maidhof HP, Trauer H, Wiegand J.

Am J Gastroenterol. 2019 Aug;114(8):1358-1359. doi: 10.14309/ajg.0000000000000300. No abstract available.

PMID:
31246695
7.

Evaluation of a novel tomographic ultrasound device for abdominal examinations.

Blank V, Wiegand J, Keim V, Karlas T.

PLoS One. 2019 Jun 26;14(6):e0218754. doi: 10.1371/journal.pone.0218754. eCollection 2019.

8.

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs.

Tacke F, Boeker KHW, Klinker H, Heyne R, Buggisch P, Pathil A, Wiegand J, Cornberg M, Lange C, Berg T, Zeuzem S, Mauss S.

Liver Int. 2019 Jun 26. doi: 10.1111/liv.14186. [Epub ahead of print]

PMID:
31241820
9.

Author Correction: Predicting hepatic complications of allogeneic hematopoietic stem cell transplantation using liver stiffness measurement.

Karlas T, Weiße T, Petroff D, Beer S, Döhring C, Gnatzy F, Niederwieser D, Behre G, Mössner J, Fischer J, Tröltzsch M, Wiegand J, Keim V, Franke GN.

Bone Marrow Transplant. 2019 Nov;54(11):1920. doi: 10.1038/s41409-019-0512-6.

PMID:
30890767
10.

Predicting hepatic complications of allogeneic hematopoietic stem cell transplantation using liver stiffness measurement.

Karlas T, Weiße T, Petroff D, Beer S, Döhring C, Gnatzy F, Niederwieser D, Behre G, Mössner J, Fischer J, Tröltzsch M, Wiegand J, Keim V, Franke GN.

Bone Marrow Transplant. 2019 Nov;54(11):1738-1746. doi: 10.1038/s41409-019-0464-x. Epub 2019 Feb 26. Erratum in: Bone Marrow Transplant. 2019 Mar 19;:.

PMID:
30809042
11.

[Do NAFLD-patients require HCC screening?]

Karlas T, Wiegand J, Petroff D.

Z Gastroenterol. 2019 Feb;57(2):160-161. doi: 10.1055/a-0825-7739. Epub 2019 Feb 12. German. No abstract available.

PMID:
30754062
12.

Modalities and accuracy of diagnosis of external ventricular drainage-related infections: a prospective multicentre observational cohort study.

Berger-Estilita J, Passer M, Giles M, Wiegand J, Merz TM.

Acta Neurochir (Wien). 2018 Oct;160(10):2039-2047. doi: 10.1007/s00701-018-3643-4. Epub 2018 Jul 31.

13.

Age-associated changes in waking hippocampal sharp-wave ripples.

Cowen SL, Gray DT, Wiegand JL, Schimanski LA, Barnes CA.

Hippocampus. 2020 Jan;30(1):28-38. doi: 10.1002/hipo.23005. Epub 2018 Nov 11.

14.

Predictive value of liver and spleen stiffness in advanced alcoholic cirrhosis with refractory ascites.

Lindner F, Mühlberg R, Wiegand J, Tröltzsch M, Hoffmeister A, Keim V, Karlas T.

Z Gastroenterol. 2018 Jun;56(6):561-568. doi: 10.1055/a-0572-7172. Epub 2018 Jun 11.

PMID:
29890557
15.

Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study.

Grimaldi-Bensouda L, Wedemeyer H, Wiegand J, Lohse AW, Benichou J, Rossignol M, Larrey D, Abenhaim L, Poynard T, Schott E; PGRx-ALI study group.

Int J Cardiol. 2018 Sep 1;266:100-105. doi: 10.1016/j.ijcard.2018.04.007.

PMID:
29887424
16.

Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.

Petroff D, Blüher M, Wiegand J.

Dig Liver Dis. 2018 Jul;50(7):731-733. doi: 10.1016/j.dld.2018.03.029. Epub 2018 Mar 30. No abstract available.

PMID:
29699861
17.

Editorial: the impact of steatosis on liver stiffness quantification is minimal-Authors' reply.

Karlas T, Petroff D, Wiegand J.

Aliment Pharmacol Ther. 2018 May;47(10):1417-1418. doi: 10.1111/apt.14632. No abstract available.

18.

Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement.

Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Lee HW, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J.

Aliment Pharmacol Ther. 2018 Apr;47(7):989-1000. doi: 10.1111/apt.14529. Epub 2018 Feb 15.

19.

Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting.

Lüllau A, Petroff D, Bätz O, Kramer J, Jedrysiak K, Tenckhoff H, Berg T, Wolffram I, Wiegand J.

Eur J Gastroenterol Hepatol. 2018 Mar;30(3):280-283. doi: 10.1097/MEG.0000000000001052.

PMID:
29324587
20.

Interfacial Molecular Packing Determines Exciton Dynamics in Molecular Heterostructures: The Case of Pentacene-Perfluoropentacene.

Rinn A, Breuer T, Wiegand J, Beck M, Hübner J, Döring RC, Oestreich M, Heimbrodt W, Witte G, Chatterjee S.

ACS Appl Mater Interfaces. 2017 Dec 6;9(48):42020-42028. doi: 10.1021/acsami.7b11118. Epub 2017 Nov 27.

PMID:
29135216
21.

Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting.

Barth C, Neusser S, Biermann J, Wasem J, Berg T, Wiegand J, Wolffram I, Petroff D, Aidelsburger P, Grünbauer A, Neumann A.

Scand J Gastroenterol. 2018 Jan;53(1):76-82. doi: 10.1080/00365521.2017.1390599. Epub 2017 Oct 24.

PMID:
29065740
22.

Highly anisotropic electric conductivity in PAN-based carbon nanofibers.

Aprojanz J, Dreyer B, Wehr M, Wiegand J, Baringhaus J, Koch J, Renz F, Sindelar R, Tegenkamp C.

J Phys Condens Matter. 2017 Dec 13;29(49):494002. doi: 10.1088/1361-648X/aa9494.

PMID:
29047449
23.

Acute developmental exposure to 4-hydroxyandrostenedione has a long-term effect on visually-guided behaviors.

Gould CJ, Wiegand JL, Connaughton VP.

Neurotoxicol Teratol. 2017 Nov;64:45-49. doi: 10.1016/j.ntt.2017.10.003. Epub 2017 Oct 12.

PMID:
29031477
24.

Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease.

Ebert T, Linder N, Schaudinn A, Busse H, Berger J, Lichtinghagen R, Keim V, Wiegand J, Karlas T.

Endocrine. 2017 Nov;58(2):246-252. doi: 10.1007/s12020-017-1417-z. Epub 2017 Sep 15.

PMID:
28914407
25.

Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease.

Karlas T, Weise L, Kuhn S, Krenzien F, Mehdorn M, Petroff D, Linder N, Schaudinn A, Busse H, Keim V, Pratschke J, Wiegand J, Splith K, Schmelzle M.

J Transl Med. 2017 May 19;15(1):106. doi: 10.1186/s12967-017-1208-6.

26.

Platform to Enable Combined Measurement of Dopamine and Neural Activity.

Parent KL, Hill DF, Crown LM, Wiegand JP, Gies KF, Miller MA, Atcherley CW, Heien ML, Cowen SL.

Anal Chem. 2017 Mar 7;89(5):2790-2799. doi: 10.1021/acs.analchem.6b03642. Epub 2017 Feb 17.

27.

Do we need controlled attenuation parameter adjustment for fibrosis estimation in nonalcoholic fatty liver disease patients?

Karlas T, Beer S, Babel J, Busse H, Schaudinn A, Linder N, Wiegand J, Petroff D.

Hepatology. 2017 Jun;65(6):2126-2128. doi: 10.1002/hep.29067. Epub 2017 Apr 24. No abstract available.

PMID:
28103641
28.

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.

Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J.

J Hepatol. 2017 May;66(5):1022-1030. doi: 10.1016/j.jhep.2016.12.022. Epub 2016 Dec 28.

PMID:
28039099
29.

Collaboration, Not Competition: The Role of Magnetic Resonance, Transient Elastography, and Liver Biopsy in the Diagnosis of Nonalcoholic Fatty Liver Disease.

Karlas T, Petroff D, Wiegand J.

Gastroenterology. 2017 Feb;152(3):479-481. doi: 10.1053/j.gastro.2016.12.013. Epub 2016 Dec 27. No abstract available.

PMID:
28038929
30.

Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.

Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, Spengler U, Wiegand J, Schulze Zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zöllner C, Zeuzem S, Papkalla A, Weber K, Hardtke S, von der Leyen H, Koch A, von Witzendorff D, Manns MP, Wedemeyer H; HepNet Acute HCV IV Study Group.

Lancet Infect Dis. 2017 Feb;17(2):215-222. doi: 10.1016/S1473-3099(16)30408-X. Epub 2016 Oct 28.

PMID:
28029529
31.

Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection.

Graf Einsiedel H, Christiansen H, Wiegand J.

Pediatr Infect Dis J. 2016 Dec;35(12):1373. No abstract available.

PMID:
27832030
32.

Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders.

Wiegand J, Schiefke I, Stein K, Berg T, Kullig U, Ende K.

Hamostaseologie. 2017 May 10;37(2):127-130. doi: 10.5482/HAMO-16-05-0014. Epub 2016 Jul 15.

PMID:
27416915
33.

Hepatitis B Vaccination in End-Stage Pulmonary Disease Patients Evaluated for Lung Transplantation: A Retrospective Single-Center Evaluation.

Wald A, Deterding L, Maier M, Liebert UG, Berg T, Wirtz H, Wiegand J.

Ann Transplant. 2016 Jun 14;21:368-72.

34.

Age Is Associated with Reduced Sharp-Wave Ripple Frequency and Altered Patterns of Neuronal Variability.

Wiegand JP, Gray DT, Schimanski LA, Lipa P, Barnes CA, Cowen SL.

J Neurosci. 2016 May 18;36(20):5650-60. doi: 10.1523/JNEUROSCI.3069-15.2016.

35.

HBsAg and anti-HCV screening in elderly hospitalized patients of a German tertiary referral centre.

Kant J, Kratzsch J, Maier M, Liebert UG, Berg T, Wiegand J.

Z Gastroenterol. 2016 Mar;54(3):231-7. doi: 10.1055/s-0041-106656. Epub 2016 Apr 4.

PMID:
27043886
36.

A Pilot Study of Perceptual-Motor Training for Peripheral Prisms.

Houston KE, Bowers AR, Fu X, Liu R, Goldstein RB, Churchill J, Wiegand JP, Soo T, Tang Q, Peli E.

Transl Vis Sci Technol. 2016 Feb 22;5(1):9. eCollection 2016 Feb.

37.

Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015.

Wiegand J, van Bömmel F, Duarte-Rojo A, Altamirano J, Abraldes JG, Villanueva A, Berg T.

J Hepatol. 2016 Jun;64(6):1428-45. doi: 10.1016/j.jhep.2016.02.020. Epub 2016 Feb 21. Review. No abstract available.

PMID:
26902945
38.

Indicators of external ventricular drainage-related infections--a retrospective observational study.

Wiegand J, Hickson L, Merz TM.

Acta Neurochir (Wien). 2016 Mar;158(3):595-601; discussion 601. doi: 10.1007/s00701-016-2709-4. Epub 2016 Jan 25.

PMID:
26811299
39.

Urinary Peptide Analysis Differentiates Pancreatic Cancer From Chronic Pancreatitis.

Schönemeier B, Metzger J, Klein J, Husi H, Bremer B, Armbrecht N, Dakna M, Schanstra JP, Rosendahl J, Wiegand J, Jäger M, Mullen W, Breuil B, Plentz RR, Lichtinghagen R, Brand K, Kühnel F, Mischak H, Manns MP, Lankisch TO.

Pancreas. 2016 Aug;45(7):1018-26. doi: 10.1097/MPA.0000000000000573.

PMID:
26784907
40.

Letter: can persisting liver stiffness indicate increased risk of HCC, after successful anti-HCV therapy?

Karlas T, Benckert J, Beer S, Keim V, Berg T, Wiegand J.

Aliment Pharmacol Ther. 2016 Feb;43(4):543-4. doi: 10.1111/apt.13479. No abstract available.

41.

Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity.

Deterding K, Grüner N, Buggisch P, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Grohennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H, Wiegand J; Hep-Net Acute HCV-III Study Group.

Eur J Gastroenterol Hepatol. 2016 Feb;28(2):187-92. doi: 10.1097/MEG.0000000000000517.

PMID:
26575158
42.

Evaluation of Transient Elastography, Acoustic Radiation Force Impulse Imaging (ARFI), and Enhanced Liver Function (ELF) Score for Detection of Fibrosis in Morbidly Obese Patients.

Karlas T, Dietrich A, Peter V, Wittekind C, Lichtinghagen R, Garnov N, Linder N, Schaudinn A, Busse H, Prettin C, Keim V, Tröltzsch M, Schütz T, Wiegand J.

PLoS One. 2015 Nov 3;10(11):e0141649. doi: 10.1371/journal.pone.0141649. eCollection 2015.

43.

Therapy of Liver Abscesses.

Lübbert C, Wiegand J, Karlas T.

Viszeralmedizin. 2014 Oct;30(5):334-41. doi: 10.1159/000366579. Review.

44.

Metabolically programmed iron chelators.

Bergeron RJ, Bharti N, McManis JS, Wiegand J.

Bioorg Med Chem. 2015 Sep 1;23(17):5954-71. doi: 10.1016/j.bmc.2015.06.059. Epub 2015 Jun 29.

45.

Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.

Karlas T, Berger J, Garnov N, Lindner F, Busse H, Linder N, Schaudinn A, Relke B, Chakaroun R, Tröltzsch M, Wiegand J, Keim V.

World J Gastroenterol. 2015 Apr 28;21(16):4894-902. doi: 10.3748/wjg.v21.i16.4894.

46.

The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax).

Al-Batran SE, Hozaeel W, Tauchert FK, Hofheinz RD, Hinke A, Windemuth-Kieselbach C, Hübner A, Burmester M, Koenigsmann M, Wiegand J, Zur Hausen G, Linsse B, Kuhl R, Pauligk C; Arbeitsgemeinschaft Internistische Onkologie (AIO).

Ann Oncol. 2015 Jun;26(6):1244-8. doi: 10.1093/annonc/mdv129. Epub 2015 Mar 9.

47.

Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios.

Wolffram I, Petroff D, Bätz O, Jedrysiak K, Kramer J, Tenckhoff H, Berg T, Wiegand J; German Check-Up 35+ Study Group.

J Hepatol. 2015 Jun;62(6):1256-64. doi: 10.1016/j.jhep.2015.01.011. Epub 2015 Jan 21.

PMID:
25617500
48.

Noninvasive characterization of graft steatosis after liver transplantation.

Karlas T, Kollmeier J, Böhm S, Müller J, Kovacs P, Tröltzsch M, Weimann A, Bartels M, Rosendahl J, Mössner J, Berg T, Keim V, Wiegand J.

Scand J Gastroenterol. 2015 Feb;50(2):224-32. doi: 10.3109/00365521.2014.983156. Epub 2014 Nov 27.

PMID:
25429378
49.

Oxygen kinetics during 6-minute walk tests in patients with cardiovascular and pulmonary disease.

Kern L, Condrau S, Baty F, Wiegand J, van Gestel AJ, Azzola A, Tamm M, Brutsche M.

BMC Pulm Med. 2014 Oct 29;14:167. doi: 10.1186/1471-2466-14-167.

50.

Swiss Monitoring of Potential Organ Donors (SwissPOD): a prospective 12-month cohort study of all adult ICU deaths in Switzerland.

Weiss JH, Keel I, Immer FF, Wiegand J, Haberthür C; Comité National du Don d'Organes (CNDO).

Swiss Med Wkly. 2014 Oct 23;144:w14045. doi: 10.4414/smw.2014.14045. eCollection 2014.

Supplemental Content

Loading ...
Support Center